You are currently viewing Ehave KetaDASH Subsidiary Announces Intent to Battle Major Depression through Home Delivery of Ketamine

Ehave KetaDASH Subsidiary Announces Intent to Battle Major Depression through Home Delivery of Ketamine

Ketamine, originally approved by the FDA for anesthesia and pain relief, is now one of the psychedelics compounds being studied to treat mental health conditions like anxiety, addiction, and depression.

MIAMI, Dec. 23, 2020 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, today announced it intends to offer home infusion of ketamine for patients whose healthcare provider has prescribed it as a treatment. Through its recently formed KetaDASH ( subsidiary, Ehave will provide medical professionals with the platform for home IV delivery. The platform will include software, protocols, and equipment, as well as a smart and intuitive dashboard for KetaDash designed to help patients and medical professionals interact.

Ehave Chief Executive Officer, Ben Kaplan, said, “The main reason we are focusing on ketamine as a psychedelic-assisted therapy is to present a new treatment for individuals suffering from depression, anxiety, PTSD or other mental or emotional health challenges. Our goal is to provide an IV service that will allow medical professionals to provide psychedelic-assisted therapies in the comfort and convenience of their patients’ homes. We believe a large number of patients prefer a medical technician come to their home over going to a clinic.”

Lisa Ling, who hosts “This is Life” on CNN, recently aired a special on the psychedelic treatment revolution and how ketamine has been successfully repurposed over the past few years to treat depression and PTSD. The report is available online at

Victor S. Dorodny, MD,ND,PHD,MPH (, Medical Advisor to Ehave, said, “Ketamine, a widely used anesthetic medication, is now being used to treat depression, suicidality, chronic pain, migraines, OCD and even some PTSD symptoms. For many, this breakthrough treatment represents a powerful opportunity to manage their mental health challenges. KetaDash will allow the patients who are prescribed Ketamine to receive required treatments in the safety and comfort of their homes.”

Additional Ehave Inc. Information

We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at

The company posts important information and updates through weekly videos from the official company YouTube channel

Please follow Ehave on Twitter @Ehaveinc1

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit:

About KetaDASH

KetaDash is a smart and intuitive dashboard designed for those giving and receiving Ketamine infusion therapy. Clients and the associated medical professionals can get detailed insight on the progress and effectiveness of the therapy. Patients can check the availability of nearby nurses, who can help them get their therapy in their own home. KetaDash lets you easily create your profile, check availability of the nurses, and schedule your appointment.

Patients and nurses, both can check the scheduled appointment details from their end. Also, when a client requests for a therapy, a nurse can accept or reject it depending on their availability.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website,

For Investor Relations, please contact:

Gabe Rodriguez

Phone: (623) 261-9046